Literature DB >> 17185364

Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen Risk and Cardiovascular Health study).

Andreas Meinitzer1, Ursula Seelhorst, Britta Wellnitz, Gabriele Halwachs-Baumann, Bernhard O Boehm, Bernhard R Winkelmann, Winfried März.   

Abstract

BACKGROUND: Asymmetrical dimethylarginine (ADMA) is increased in conditions associated with increased risk of atherosclerosis. We investigated the use of ADMA to predict total and cardiovascular mortality in patients scheduled for coronary angiography.
METHODS: In 2543 persons with and 695 without coronary artery disease (CAD) identified by angiography we measured ADMA and recorded total and cardiovascular mortality during a median follow-up of 5.45 years.
RESULTS: ADMA was correlated positively to age, female sex, diabetes mellitus, former and current smoking, and C-reactive protein and inversely to HDL cholesterol and triglycerides. ADMA was not associated with body mass index, hypertension, LDL cholesterol, or the presence or absence of angiographic CAD. Glomerular filtration rate and homocysteine were the strongest predictors of ADMA. At the 2nd, 3rd and 4th quartile of ADMA, hazard ratios for all-cause mortality adjusted for age, sex, and cardiovascular risk factors were 1.12 [95% confidence interval (CI) 0.83-1.52], 1.35 (95% CI 1.01-1.81), and 1.87 (95% CI 1.43-2.44), respectively, compared with the 1st quartile. Hazard ratios for cardiovascular death were 1.13 (95% CI 0.78-1.63), 1.42 (95% CI 1.00-2.02), and 1.81 (95% CI 1.31-2.51). ADMA in the highest quartile remained predictive of mortality after accounting for medication at baseline. The predictive value of ADMA was similar to that in the entire cohort in persons with CAD, stable or unstable, but was not statistically significant in persons without angiographic CAD.
CONCLUSIONS: ADMA concentration predicts all-cause and cardiovascular mortality in individuals with CAD independently of established and emerging cardiovascular risk factors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17185364     DOI: 10.1373/clinchem.2006.076711

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  61 in total

1.  Asymmetric Dimethylarginine Predicts One-year Recurrent Cardiovascular Events: Potential Biomarker of "Toxin Syndrome" in Coronary Heart Disease.

Authors:  Hao Xu; Zhuo Chen; Qing-Hua Shang; Zhu-Ye Gao; Chang-An Yu; Da-Zhuo Shi; Ke-Ji Chen
Journal:  Chin J Integr Med       Date:  2019-05-07       Impact factor: 1.978

2.  Association between endothelial dysfunction and frailty: the Toledo Study for Healthy Aging.

Authors:  Cristina Alonso-Bouzón; Laure Carcaillon; Francisco J García-García; María S Amor-Andrés; Mariam El Assar; Leocadio Rodríguez-Mañas
Journal:  Age (Dordr)       Date:  2014-02

3.  Symmetric dimethylarginine as a proinflammatory agent in chronic kidney disease.

Authors:  Eva Schepers; Daniela V Barreto; Sophie Liabeuf; Griet Glorieux; Sunny Eloot; Fellype C Barreto; Ziad Massy; Raymond Vanholder
Journal:  Clin J Am Soc Nephrol       Date:  2011-08-04       Impact factor: 8.237

4.  A novel predictor of restenosis and adverse cardiac events: asymmetric dimethylarginine.

Authors:  Hasan Ari; Selma Ari; Ercan Erdoğan; Osman Tiryakioğlu; Yasemin Ustündağ; Kağan Huysal; Vedat Koca; Tahsin Bozat
Journal:  Heart Vessels       Date:  2010-01-21       Impact factor: 2.037

5.  Dimethylarginine dimethylaminohydrolase overexpression ameliorates atherosclerosis in apolipoprotein E-deficient mice by lowering asymmetric dimethylarginine.

Authors:  Johannes Jacobi; Renke Maas; Arturo J Cardounel; Michaela Arend; Arthur J Pope; Nada Cordasic; Juliane Heusinger-Ribeiro; Dorothee Atzler; Joachim Strobel; Edzard Schwedhelm; Rainer H Böger; Karl F Hilgers
Journal:  Am J Pathol       Date:  2010-03-26       Impact factor: 4.307

6.  Asymmetric dimethylarginine in angiotensin II-induced hypertension.

Authors:  Jennifer M Sasser; Natasha C Moningka; Mark W Cunningham; Byron Croker; Chris Baylis
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-12-16       Impact factor: 3.619

7.  Asymmetric dimethylarginine predicts survival in the elderly.

Authors:  Francesco Pizzarelli; Renke Maas; Pietro Dattolo; Giovanni Tripepi; Stefano Michelassi; Graziella D'Arrigo; Maren Mieth; Stefania Bandinelli; Luigi Ferrucci; Carmine Zoccali
Journal:  Age (Dordr)       Date:  2013-04-13

8.  Coronary artery calcification, ADMA, and insulin resistance in CKD patients.

Authors:  Shuzo Kobayashi; Machiko Oka; Kyoko Maesato; Ryota Ikee; Tsutomu Mano; Moriya Hidekazu; Takayasu Ohtake
Journal:  Clin J Am Soc Nephrol       Date:  2008-06-18       Impact factor: 8.237

9.  ADMA and SDMA levels in healthy men exposed to tobacco smoke.

Authors:  Andrzej Sobczak; Maciej Lukasz Goniewicz; Izabela Szoltysek-Boldys
Journal:  Atherosclerosis       Date:  2009-01-09       Impact factor: 5.162

10.  The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease.

Authors:  Latika Sibal; Sharad C Agarwal; Philip D Home; Rainer H Boger
Journal:  Curr Cardiol Rev       Date:  2010-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.